# Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

> **NCT02331368** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 32 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **PROCEDURE:** Autologous Stem Cell Transplant
- **DRUG:** Melphalan
- **DRUG:** Lenalidomide
- **DRUG:** MK-3475

## Key facts

- **NCT ID:** NCT02331368
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02331368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02331368, "Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02331368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*